Huahai Pharmaceutical (600521.SH) obtained the drug registration certificate for levocarnitine injection

Zhitong Financial App News, Huahai Pharmaceutical (600521.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for levocarnitine injections approved and issued by the State Drug Administration (“State Drug Administration”). Levocarnitine injections are used for a series of complications caused by secondary carnitine deficiency in patients with chronic renal failure. Clinical manifestations include cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, and muscle spasms during dialysis.

According to relevant national policies, the company approved production of levocarnitine injections according to the 4 categories of chemicals can be considered to have passed the consistency evaluation. The approval of this product further enriches the company's product line and helps enhance the market competitiveness of the company's products.